

Edward Cappabianca
Founder & Director
EnXray Limited
Liverpool Innovation Park,
Edge Lane,
Liverpool
L7 9NJ

13th December 2017

Dear Ed,

RE: Working with EnXray Limited on applications of EnXray's Low Energy X-ray (LEXR) technology in the cell and gene therapy industry

The cell and gene therapy sector is one of the most rapidly growing sectors of innovation in healthcare and is often compared in its potential to the monoclonal antibody industry, which has grown from similar roots to be an \$80bn+ global industry. The Cell and Gene Therapy Catapult (CGTC) is a research organisation funded and mandated to help companies in the UK cell and gene therapy industry thrive, and in doing so capture a disproportionate share of this global industry in the UK. One of the ways that we fulfill our mandate is to identify technological gaps in the industry and work with companies to develop new technologies to meet a market opportunity.


One of the key waves of our strategy is titled "Intelligent Manufacture and Productivity" and seeks to allow the industry to scale up efficiently to meet the anticipated demand for product. Within this work programme, one of the identified areas of need is efficient and automated downstream processing: which is in the early stages of evolution. There is a need and opportunity within this for appropriate new technologies for terminal inactivation and sterilisation.

CGTC is working closely with EnXray to develop new commercial applications of the LEXR technology in the development and eventual commercialisation of advanced therapies. Our portfolio contains a number of active projects in both large and small scale downstream processing, for which there are no commercially practical solutions for terminal inactivation and sterilisation. We believe EnXray's LEXR technology may work well in some of these technology gaps and are actively seek to bring researchers, and potential users and customers for the product, into collaborations to accelerate the commercial development of the technology.

We have recently submitted a substantial Innovate-UK grant proposal with you for Collaborative Research and Development Funding for a specific potential application

Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT. VAT number 154 4214 33.

+44(0)20 3728 9500 ct.catapult.org.uk



of the LEXR technology, but our interest in EnXray's technology does not stop there. We look forward to continuing to work with you to identify other commercial applications of the technology as well as other sources of research and development funding as your company develops.

Any specific information that we share about opportunities, technologies and projects will need to be governed by a separate confidentiality and non-disclosure agreement but we are happy for you to share the contents of this letter with interested parties.

Yours sincerely

DocuSigned by:

AA8FA80329024F7...

December 13, 2017 | 09:10 GMT

Matthew Durdy

Chief Business Officer and Director

More information on our activities can be found at:

<https://ct.catapult.org.uk/>

Or in the attached 2017 Annual Review



Adobe Acrobat
Document

Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT. VAT number 154 4214 33.

+44(0)20 3728 9500 ct.catapult.org.uk